PharmAust to reformulate MPL
PharmAust has appointed Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, to reformulate monepantel (MPL) for its phase II studies currently in planning and preparation.
- AAP, THE AUSTRALIAN
- JANUARY 11, 2016 1:02PM
UK based Juniper Pharma Services will also manufacture 20,000 capsules of the reformulated MPL solution under good manufacturing practice, ensuring that the phase II data are admissible to regulators as part of any subsequent submissions. It will optimise formulation performance through its science-led approach to projects.
The primary need to reformulate MPL stems from the particularly unpleasant taste of the current MPL formulation, as used at the Royal Adelaide Hospital during the phase II study.
http://www.theaustralian.com.au/new...l/news-story/63ae1e7b0d77dd7da0b87ba3046ab6d3
Ann: Juniper Pharma Services to reformulate MPL for Phase II, page-5
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.77M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.0¢ | 19.0¢ | $62.98K | 324.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 108063 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 197665 | 4 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |